Meyerovitz M F
Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
J Vasc Interv Radiol. 1995 Nov-Dec;6(6 Pt 2 Suppl):62S-65S. doi: 10.1016/s1051-0443(95)71250-7.
Fibrinolytic therapy has become an accepted treatment modality for recent peripheral arterial and bypass graft occlusions and, in some cases, for chronic arterial occlusions. Streptokinase, urokinase, and tissue plasminogen activator have all been used for intraarterial infusion with varying protocols and results. This review focuses on dosing variables and clinical results for the various thrombolytic agents in peripheral arterial and bypass graft occlusions. Also discussed are new thrombolytic agents and the effects of concomitant use of other drugs as part of the treatment regimen.
纤维蛋白溶解疗法已成为近期外周动脉和旁路移植血管闭塞的一种公认治疗方式，在某些情况下，也用于慢性动脉闭塞。链激酶、尿激酶和组织型纤溶酶原激活剂均已用于动脉内输注，其方案和结果各不相同。本综述重点关注各种溶栓药物在外周动脉和旁路移植血管闭塞中的剂量变量和临床结果。还讨论了新型溶栓药物以及作为治疗方案一部分同时使用其他药物的效果。
